We describe an ALG9-defective (congenital disorders of glycosylation type IL) patient who is homozygous for the p.Y286C (c.860A>G) mutation. This patient presented with psychomotor retardation, axial hypotonia, epilepsy, failure to thrive, inverted nipples, hepatomegaly, and pericardial effusion. Due to the ALG9 deficiency, the cells of this patient accumulated the lipid-linked oligosaccharides Man 6 GlcNAc 2 -PP-dolichol and Man 8 GlcNAc 2 -PP-dolichol. It is known that the oligosaccharide structure has a profound effect on protein glycosylation. Therefore, we investigated the influence of these truncated oligosaccharide structures on the protein transfer efficiency, the quality control of newly synthesized glycoproteins, and the eventual degradation of the truncated glycoproteins formed in this patient. We demonstrated that lipid-linked Man 6 GlcNAc 2 and Man 8 GlcNAc 2 are transferred onto proteins with the same efficiency. In addition, glycoproteins bearing these Man 6 GlcNAc 2 and Man 8 GlcNAc 2 structures efficiently entered in the glucosylation/deglucosylation cycle of the quality control system to assist in protein folding. We also showed that in comparison with control cells, patient's cells degraded misfolded glycoproteins at an increasing rate. The Man 8 GlcNAc 2 isomer C on the patient's glycoproteins was found to promote the degradation of misfolded glycoproteins.
Introduction
N-Glycosylation of proteins is a widespread posttranslational modification, crucial for the development, growth, function, and survival of organisms (Varki 1993) . The N-linked glycosylation pathway starts with the assembly of the Glc 3 Man 9 GlcNAc 2 oligosaccharide precursor on a P-dolichol carrier in the Endoplasmic Reticulum (ER) membrane. Once synthesized, this structure is transferred onto nascent polypeptide chains by the oligosaccharyltransferase (OST) complex. Subsequently, the Glc 3 Man 9 GlcNAc 2 oligosaccharide is deglucosylated by the combined action of glucosidase I and II, leaving a Man 9 GlcNAc 2 oligosaccharide on the proteins (Parodi 2000) .
The fate of newly synthesized glycoproteins is determined during the quality control system in the ER lumen. This quality control system ensures that (1) only correctly folded glycoproteins leave the ER, (2) misfolded glycoproteins are assisted in their folding, and (3) irreversibly misfolded proteins are retro-translocated to the cytosol for degradation. One of the key steps in the quality control of newly synthesized glycoproteins is mediated by the action of UDP-Glc:glycoprotein glucosyltransferase (UGGT) and glucosidase II. UGGT, considered as a sensor for protein folding, recognizes hydrophobic regions on incorrectly folded glycoproteins and reglucosylates the protein-linked Man 9 GlcNAc 2 oligosaccharide. This reglucosylation event allows the resulting Glc 1 Man 9 GlcNAc 2 to interact with molecular chaperones such as calnexin and calreticulin, which assist in protein folding. Finally, glucosidase II removes again the glucose residue to allow the release of the folded glycoproteins. Correctly folded glycoproteins then leave the ER and are transported to the appropriate destination, while partially folded glycoproteins enter once more in the glucosylation/ deglucosylation cycle until folding is complete (Parodi 2000) .
If glycoproteins fail to fold correctly after several cycles of reglucosylation and deglucosylation, the Man 9 GlcNAc 2 oligosaccharide is converted into the Man 8 GlcNAc 2 isomer B by the action of ER mannosidase I. The formation of this Man 8 GlcNAc 2 isomer B signals the unfolded glycoproteins for degradation via the ER-associated degradation (ERAD) pathway (Jakob et al. 1998; Cabral et al. 2001 ). This ERAD pathway constitutes the retro-translocation of misfolded glycoproteins from the ER to the cytosol, followed by the release of the oligosaccharides by a peptide N-glycanase activity Suzuki and Funakoshi 2006) . The resulting free oligosaccharides bear two GlcNAc residues at their reducing ends (called OSGn2). Further degradation of these free oligosaccharides in the cytosol occurs via the trimming by a chitobiase, resulting in the formation of oligosaccharides having one GlcNAc residue at their reducing ends (called OSGn1). Moreover, these OSGn1 species are converted into a specific Man 5 GlcNAc 1 structure by a cytosolic mannosidase (Kmiécik et al. 1995; Cacan et al. 1996) .
The oligosaccharide structures play an important role during the glycosylation pathway. On the one hand, the integrity of the lipid-linked oligosaccharides (LLO) influences the protein transfer rate, and therefore the appearance of hypoglycosylated protein forms: nonglucosylated oligosaccharide structures are Quality control of glycoproteins in an ALG9-defective (CDG-IL) patient 20-to 25-fold less efficiently transferred onto proteins in comparison with their fully glucosylated forms (Turco et al. 1977; Trimble et al. 1980; Karaoglu et al. 2001) . On the other hand, the structure of the protein-bound oligosaccharide has a profound effect on the protein quality control and the recycling of misfolded glycoproteins in the glucosylation/deglucosylation cycle. It has been shown that UGGT and glucosidase II act poorly on substrates with trimmed mannose branches (Grinna and Robbins 1980; Sousa et al. 1992) , while extensive mannose trimming retained the chaperone binding activity (Spiro et al. 1996) .
The importance of glycosylation is dramatically illustrated by a group of inherited human disorders called congenital disorders of glycosylation (CDG). Up to now, 31 different CDG types have been identified, of which 14 are caused by deficiencies in oligosaccharide precursor formation. These defects in oligosaccharide precursor formation were formerly classified as CDG type I (CDG-I) (Eklund and Freeze 2006; Leroy 2006; Freeze 2007; Jaeken and Matthijs 2007) .
In 2004, Frank and co-workers described a new type of CDG, called CDG-IL, in an infant with neuro-developmental impairment, seizures, and hepatomegaly (Frank et al. 2004 ). CDG-IL was caused by a mutation (c.1567G>A; p.E523K) in the ALG9 gene, which codes for the α1,2 mannosyltransferase catalyzing the addition of the seventh and ninth mannose residue during oligosaccharide precursor formation. One year later, Weinstein and collaborators described a second CDG-IL patient who was homozygous for the p.Y286C (c.860A>G) mutation, differing from the originally described mutation (Weinstein et al. 2005) . Due to recent changes in nomenclature, CDG-IL is now called ALG9 deficiency (CDG-IL) (Jaeken et al. 2008) .
In this study, we described an ALG9-defective (CDG-IL) patient who is homozygous for the p.Y286C (c.860A>G) mutation. Due to the accumulation of both Man 6 GlcNAc 2 and Man 8 GlcNAc 2 on LLO, the patient's fibroblasts were used to study in vivo the protein transfer efficiency of these assembly intermediates, the quality control of newly synthesized glycoproteins, and the eventual degradation of the truncated glycoproteins formed in this patient. We demonstrated that lipid-linked Man 6 GlcNAc 2 and Man 8 GlcNAc 2 are transferred onto proteins with the same efficiency. In addition, glycoproteins bearing these Man 6 GlcNAc 2 and Man 8 GlcNAc 2 structures efficiently entered in the glucosylation/deglucosylation cycle of the quality control system to assist in protein folding. We also showed that in comparison with control cells, patient's cells degraded misfolded glycoproteins at an increasing rate. The Man 8 GlcNAc 2 isomer C on the patient's glycoproteins was found to promote the degradation of misfolded glycoproteins.
Results

Clinical phenotype
The patient is the daughter of Caucasian parents that are distantly related. She was admitted at 3 months with failure to thrive, vomiting, and watery stools. Further investigations at 6.5 months revealed mild dysmorphy, mild central hypotonia, and psychomotor retardation. She was on nasogastric feeding with good catch-up growth and had less frequent episodes of unconsolable crying. In addition, she suffered from several seizures; echocardiography showed a small resolving pericardial effusion and CT scan of the brain was normal. Metabolic investigations were normal.
Biochemical and molecular diagnosis
Iso-electric focusing of serum transferrin revealed a type 1 sialotransferrin pattern in the patient, confirming the clinical suggestion of CDG-I ( Figure 1A) . Moreover, PMM2 deficiency (CDGIa), the most frequent type of CDG-I, was excluded on the basis of normal phosphomannomutase activity in the patient's fibroblasts.
In order to detect a possible defect during oligosaccharide precursor formation in the ER, LLO analysis was performed. Compared to control fibroblasts, an accumulation of the assembly intermediates Man 6 GlcNAc 2 -PP-dolichol and Man 8 GlcNAc 2 -PP-dolichol was detected in the patient's fibroblasts (Figure 1 , panels B and C), suggesting a deficiency in the ALG9 α(1,2)-mannosyltransferase. Sequencing of the patient's DNA revealed indeed a homozygous missense mutation c.860A>G (p.Y286C) in the ALG9 gene, and both parents were shown to be carriers for this mutation ( Figure 1D ).
Transfer of Man 6 GlcNAc 2 and Man 8 GlcNAc 2 onto proteins
Due to the accumulation of both lipid-linked Man 6 GlcNAc 2 and Man 8 GlcNAc 2 , the fibroblasts of this patient provided a good model to analyze and compare in vivo the transfer rate of these intermediates onto proteins. Hence, the structure of the oligosaccharides transferred onto proteins was analyzed after metabolic labeling of the patient's fibroblasts. Man 8 GlcNAc 2 , Man 9 GlcNAc 2 , and Glc 1 Man 9 GlcNAc 2 structures were found on the glycoproteins of control fibroblasts, whereas mainly Man 6 GlcNAc 2 and Man 8 GlcNAc 2 structures were detected on the patient's glycoproteins (Figure 2 , panels A and B). Moreover, kifunensin treatment did not influence the patient's HPLC profile ( Figure 2C ). We thus concluded that the species accumulating on LLO were transferred onto proteins, although they were not optimal substrates for the OST complex.
Intriguingly, both species were transferred with the same efficiency. By comparing the ratios of Man 6 GlcNAc 2 / Man 8 GlcNAc 2 on LLO and glycoproteins, a value of 2.98 (±0.27; n = 3) was obtained for the LLO, while a value of 2.99 (±0.14; n = 3) was found on the glycoproteins (for the calculation of the ratios, see Material and methods). The addition of kifunensin during these metabolic labelings was essential to avoid a mixture of the transferred Man 8 GlcNAc 2 structure with the Man 8 GlcNAc 2 formed by demannosylation of the Man 9 GlcNAc 2 structure. The obtained ratios suggested an equal protein transfer rate of Man 6 GlcNAc 2 and Man 8 GlcNAc 2 species. Changing the duration of metabolic labeling from 1 h to 30 min, 2 h, or 4 h did not influence the obtained ratios (data not shown). Figure 2B , two other peaks (X 1 and X 2 ) were detected on the patient's glycoproteins. Peaks X 1 and X 2 migrated as Glc 1 Man 6 GlcNAc 2 and Glc 1 Man 8 GlcNAc 2 , respectively. To confirm their identity, a metabolic labeling in presence of kifunensin and castanospermin, the latter being an inhibitor of glucosidase I and II, was carried out. In the presence W Vleugels et al. of kifunensin and castanospermin, mainly Glc 3 Man 9 GlcNAc 2 was found on the glycoproteins of control fibroblasts (data not shown), whereas only a small amount of Glc 3 Man 9 GlcNAc 2 was detected in the patient. However, the levels of X 1 and X 2 increased significantly in the glycoproteins fraction of the patient ( Figure 2D ). Additionally, treatment of the glycoproteins with glucosidase II resulted in a significant decrease in the levels of X 1 and X 2 in combination with an increase in Man 6 GlcNAc 2 and Man 8 GlcNAc 2 ( Figure 2E ). From these results, we concluded that X 1 and X 2 referred to Glc 1 Man 6 GlcNAc 2 and Glc 1 Man 8 GlcNAc 2 , respectively.
Reglucosylation of Man
Because Glc 1 Man 6 GlcNAc 2 and Glc 1 Man 8 GlcNAc 2 can be formed by deglucosylation of Glc 3 Man 6 GlcNAc 2 and Glc 3 Man 8 GlcNAc 2 , respectively, we checked the presence of these latter species on the LLO and/or glycoproteins in the patient's fibroblasts. In the presence of kifunensin and castanospermin, triglucosylated oligosaccharides (X 3 : potentially Glc 3 Man 8 GlcNAc 2 and X 4 : potentially Glc 3 Man 6 GlcNAc 2 ) did appear on the LLO and the glycoproteins, although at a very low level (Figure 2 , panels D, F, and G). This result excluded that Glc 1 Man 6 GlcNAc 2 and Glc 1 Man 8 GlcNAc 2 oligosaccharides were formed by deglucosylation of triglucosylated species. Moreover, we did not detect monoglucosylated Man 6 GlcNAc 2 or Man 8 GlcNAc 2 species on the LLO after metabolic labeling in the presence of kifunensin and castanospermin (Figure 2 , panels F and G).
All together, these results demonstrated that Glc 1 Man 6 GlcNAc 2 and Glc 1 Man 8 GlcNAc 2 structures were formed by reglucosylation of the Man 6 GlcNAc 2 and Man 8 GlcNAc 2 structures transferred onto proteins. When comparing the efficiency of reglucosylation, only minor differences in the reglucosylation of Man 6 GlcNAc 2 and Man 8 GlcNAc 2 were detected. A comparison of the ratios Glc 1 Man 6 GlcNAc 2 /Man 6 GlcNAc 2 and Glc 1 Man 8 GlcNAc 2 /Man 8 GlcNAc 2 in the presence of castanospermine revealed a value of 1.25 (±0.12; n = 3) and 1.78 (±0.08; n = 3) respectively (for the calculation of the ratios, see Material and methods). These data suggested that the Man 6 GlcNAc 2 structure was only 30% less glucosylated than the Man 8 GlcNAc 2 structure.
Preferential degradation of Man 8 GlcNAc 2
To study the fate of the truncated glycoproteins in the patient, we analyzed the free oligosaccharides, which are the degradation products of the misfolded glycoproteins Suzuki and Funakoshi 2006) . First, we compared the total amount of free oligosaccharides formed in control and patient's fibroblasts. After metabolic labeling, patient's cells incorporated 14.20% (±0.58; n = 3) of total radioactivity in the free oligosaccharides, while only 6.98% (±0.54; n = 3) of total radioactivity was found in control-free oligosaccharides (Figure 3) . In addition, this increased formation of free oligosaccharides in the patient resulted in a proportional decrease in the glycoproteins fraction, while the LLO remained unchanged (Figure 3) . Subsequently, the structure of the free oligosaccharides was analyzed by HPLC. The free oligosaccharide fraction of control fibroblasts contained mainly Man 8 GlcNAc 1/2 and Man 9 GlcNAc 1/2 structures, which was in accordance with the glycan structures found on the glycoproteins ( Figure 4A ). In contrast, Man 6 GlcNAc 1/2 and Man 8 GlcNAc 1/2 structures were found in the free oligosaccharides of the patient's fibroblasts, reflecting the glycan structures on the patient's glycoproteins ( Figure 4B ). However, Man 8 GlcNAc 1/2 species were better represented in the free oligosaccharide fraction. The ratio Man 6 GlcNAc 1/2 /Man 8 GlcNAc 1/2 reached indeed a value of 2.02 (±0.05; n = 3) in the free oligosaccharide fraction, which is in contrast to the ratio of 2.99 (±0.14; n = 3) obtained for the glycoproteins (for the calculation of the ratios, see Material and methods).
Discussion
In this paper, we described an ALG9-defective (CDG-IL) patient who is homozygous for the p.Y286C (c.860A>G) mutation, like the patient described by Weinstein et al. (2005) . The new ALG9-defective (CDG-IL) patient has a Canadian nationality, like the first patient, which could point to a founder effect of the p.Y286C mutation. Both patients showed very similar clinical pictures including psychomotor retardation, axial hypotonia, epilepsy, failure to thrive, inverted nipples, hepatomegaly, and pericardial effusion. In addition, the patient reported by Weinstein et al. (2005) showed intermittent esotropia and splenomegaly, while the present patient had more, albeit mild dysmorphic features. The ALG9-defective (CDG-IL) patient reported by Frank et al. (2004) had psychomotor retardation, axial hypotonia, epilepsy, and hepatomegaly in common with the other two patients. Other features were not mentioned in this very short report, which does not exclude their presence. Altogether, the reported ALG9-defective (CDG-IL) patients did not show a specific clinical picture. Due to the accumulation of both Man 6 GlcNAc 2 and Man 8 GlcNAc 2 on LLO, the patient's cells were used to analyze and compare in vivo the transfer rate of these accumulating intermediates onto proteins. Analysis of the patient's glycoproteins revealed the transfer of the accumulating Man 6 GlcNAc 2 and Man 8 GlcNAc 2 oligosaccharides onto proteins ( Figure 2B ). Assembly intermediates have a low affinity for the OST complex. However, transfer of accumulating assembly intermediates onto proteins has been repeatedly reported in different CDG patients (Korner et al. 1999; Kranz et al. 2001; Chantret et al. 2002 Chantret et al. , 2003 Grubenmann et al. 2002; Frank et al. 2004 ). Though, a comparison of the Man 6 GlcNAc 2 and Man 8 GlcNAc 2 transfer rate has never been done. Analysis of the glycoproteins in the ALG9-defective patient revealed an equal transfer rate for both accumulating oligosaccharides. This proved that the OST had no preference for the most entire assembled intermediate, which is the Man 8 GlcNAc 2 oligosaccharide. The donor-substrate activation model for the OST complex only favors the selective utilization of the fully assembled oligosaccharide precursor. In this model, the OST has a regulatory binding site that favors the transfer of the fully assembled oligosaccharide precursor as a function of the donor population. For this reason, the transfer of the fully assembled oligosaccharide precursor is promoted, even when this structure is not abundant (Karaoglu et al. 2001 ).
To address whether or not the Man 6 GlcNAc 2 and Man 8 GlcNAc 2 oligosaccharides were transferred onto proteins in their triglucosylated forms, a metabolic labeling in the presence of kifunensin and castanospermin was performed. Only minor triglucosylated Man 6 GlcNAc 2 and Man 8 GlcNAc 2 structures were detected on the LLO and glycoproteins (Figure 2 ). These triglucosylated forms could therefore not account for the transfer of Man 6 GlcNAc 2 and Man 8 GlcNAc 2 onto proteins. Furthermore, the absence of triglucosylated Man 7 GlcNAc 2 was reported in ALG12-defective (CDG-Ig) fibroblasts labeled in the presence of castanospermin (Chantret et al. 2002; Grubenmann et al. 2002) . From these results, we could postulate that the accumulating assembly intermediates Man 6 GlcNAc 2 , Man 7 GlcNAc 2 , and Man 8 GlcNAc 2 were not good substrates for the α1,2 glucosyltransferase I and that the presence of nine mannose residues was essential for its catalytic activity ( Figure 5A ). Glucosyltransferase I catalyzes the addition of the first glucose residue during oligosaccharide precursor formation. Analysis of the patient's glycoproteins after metabolic labeling also revealed the presence of Glc 1 Man 6 GlcNAc 2 and Glc 1 Man 8 GlcNAc 2 ( Figure 2B ). Due to the absence of monoglucosylated and triglucosylated species on LLO, we hypothesized that the monoglucosylated structures (Glc 1 Man 6 GlcNAc 2 and Glc 1 Man 8 GlcNAc 2 ) observed onto proteins were formed by the reglucosylation of Man 6 GlcNAc 2 and Man 8 GlcNAc 2 structures. While UGGT reglucosylates oligosaccharide structures transferred onto protein, these results showed that the truncated glycoproteins bearing Man 6 GlcNAc 2 and Man 8 GlcNAc 2 were incorrectly folded and entered into the glucosylation/deglucosylation cycle to improve folding. In addition, we demonstrated that UGGT efficiently reglucosylated small oligosaccharide structures such as Man 6 GlcNAc 2 : Man 6 GlcNAc 2 was only 30% less glucosylated in comparison with Man 8 GlcNAc 2 . This is in contrast to the report of Sousa et al. (1992) , where they reported a strong diminution in UGGT activity when smaller oligosaccharides were used. In this study, the relative rates for reglucosylation of Man 9 GlcNAc 2 , Man 8 GlcNAc 2 , and Man 7 GlcNAc 2 were 1.0, 0.5, and 0.15, respectively. We could thus hypothesize that, in contrast to glucosyltransferase I, mannose trimming does not impair the catalytic activity of UGGT. Moreover, studies in CHO demonstrated that Man 4 GlcNAc 2 could not be reglucosylated (Duvet et al. 2000) . Only a fully assembled α1,3 branch is thus essential for reglucosylation by UGGT ( Figure 5A ).
In parallel, analysis of the patient's glycoproteins revealed that the reglucosylated Man 6 GlcNAc 2 and Man 8 GlcNAc 2 structures were also efficiently deglucosylated. In absence of castanospermin, only a small fraction of Man 6 GlcNAc 2 and Man 8 GlcNAc 2 structures were glucosylated. On the other hand, the addition of castanospermin caused a marked increase in the fraction of reglucosylated oligosaccharides. These results tended to prove that Man 6 GlcNAc 2 and Man 8 GlcNAc 2 structures were also efficiently deglucosylated, which is in contrast to the report of Grinna and Robbins (1980) . In this study, a marked decrease in deglucosylation efficiency was obtained for substrates with trimmed mannose residues. Thanks to the efficient reglucosylation and deglucosylation of truncated glycoproteins, the cell ensures that every truncated glycoprotein can enter into the quality control system and can be recycled in the glucosylation/deglucosylation pathway. In addition, the specific activity of glucosyltransferase I ensures that only correctly assembled LLO are glucosylated during oligosaccacharide precursor assembly.
We also investigated the fate of Man 6 GlcNAc 2 and Man 8 GlcNAc 2 bearing glycoproteins by analyzing the free oligosaccharides, the degradation products of misfolded glycoproteins. Analysis of the total amount of free oligosaccharides formed in control and patient's fibroblasts revealed an increased formation of free oligosaccharides in the patient. These results showed that the degradation of misfolded glycoproteins was increased in this patient, reflecting a higher amount of misfolded glycoproteins. In addition, metabolic labeling of the patient's fibroblasts revealed that the oligosaccharide structure influences the degradation rate of misfolded glycoproteins. Glycoproteins bearing Man 8 GlcNAc 2 oligosaccharides were shown to be 34% more efficiently degraded than glycoproteins bearing a Man 6 GlcNAc 2 oligosaccharide. In a yeast study, comparing carboxypeptidase Y (CPY) bearing Man 6 GlcNAc 2 , Man 7 GlcNAc 2 , Man 8 GlcNAc 2 , and Man 9 GlcNAc 2 oligosaccharides, the Man 8 GlcNAc 2 oligosaccharide also promoted degradation of the misfolded glycoproteins (Jakob et al. 1998 ). However, the Man 8 GlcNAc 2 structure detected in our patient is not identical to the one reported by Jakob et al. (1998) : in yeast, the B-isomer of Man 8 GlcNAc 2 , generally known as the degradation signal, was investigated, while we analyzed the C isomer of Man 8 GlcNAc 2 ( Figure 5B ). Based on these results, we could postulate that the C isomer of Man 8 GlcNAc 2 also promoted degradation via the ERAD pathway or that the C-isomer is the degradation signal of another degradation pathway, like for example the nonproteasomal degradation of misfolded glycoproteins. These data were reinforced by the recent publication of Clerc et al. (2009) . They reported that N-glycans bearing a terminally α1,6-linked mannosyl residue, such as Man 7 GlcNAc 2 and Man 8 GlcNAc 2 isomer C, were a determinant directing misfolded glycoproteins to degradation.
Material and methods
Cell culture
Primary fibroblasts from controls and patient were cultured at 37
• C under 5% CO 2 in DMEM/F12 (Life Technologies, Paisley, UK) supplemented with 10% Fetal Clone III (HyClones, UT, USA). O (8:3; v/v) followed by the addition of 1.2 mL CHCl 3 . Sequential extraction of oligosaccharide materials was performed as previously described (Cacan and Verbert 1997) .
Analysis of oligosaccharide material
Free oligosaccharide fractions obtained after sequential extraction of the oligosaccharide material were desalted on Bio-Gel P2 and eluted with 5% (v/v) acetic acid. Glycoprotein fractions obtained at the end of the sequential extraction were digested overnight at room temperature with trypsin (1 mg/mL; Sigma) in the 0.1 M ammonium bicarbonate buffer, pH 7.9. The resulting glycopeptides were then treated with 0.5 U PNGase F (Roche Diagnostics, Indianapolis, IN, USA) in the 50 mM phosphate buffer, pH 7.2, for 4 h to release the oligosaccharides from the protein. Purification of the released oligosaccharides was performed as described above. Lipid-linked oligosaccharide fractions obtained after the sequential extraction were subjected to a mild acid treatment (0.1 M HCl in THF) at 50
• C for 2 h. Purification of the released oligosaccharides was performed as described above.
The oligosaccharides were separated by HPLC on a polymerbased amino column (Asahipak NH 2 P-50 column; 250 mm × 4.6 mm; Asahi, Kawasaki-ku, Japan) applying a gradient of acetonitril/H 2 O ranging from 70:30 (v/v) to 50:50 (v/v) at a flow rate of 1 mL/min over 90 min. Oligosaccharides were identified on the basis of their retention times compared to well-defined standards (Foulquier et al. 2002) . Elution of the radiolabeled oligosaccharides was monitored by continuous flow detection of radioactivity with a flo-one β detector (Packard, Les Ullis, France).
Calculation peak counts HPLC chromatograms were analyzed using the ProFSA software (Perkin Elmer, MA, USA). The counts in each peak were calculated on the basis of the peak area and normalized against the total number of counts in the injected sample. As proteinlinked Glc 1 Man 6 GlcNAc 2 and Glc 1 Man 8 GlcNAc 2 are formed by reglucosylation of Man 6 GlcNAc 2 and Man 8 GlcNAc 2 , the peak counts for the glucosylated forms were taken into account for calculating the Man 6 GlcNAc 2 /Man 8 GlcNAc 2 ratios on the glycoproteins and free oligosaccharides. In addition, the difference in mannose residues between Man 6 GlcNAc 2 and Man 8 GlcNAc 2 were taken into account.
Mutation analysis
Primers were designed to amplify the 15 exons of ALG9, including at least 50 bp of the flanking intronic regions, based on the genomic sequence of ALG9 (NM_024740). Primer sequences are available on request. The exons were amplified using standard PCR conditions, subsequently sequenced with Big Dye Terminator Ready reaction cycle sequencing kit V3.1 (Applera, Foster City, CA, USA), and analyzed on an ABI3100 Avant (Applera).
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